Skip to main content

Table 3 Plasma NfL, cognitive and motor data in PD patients over different timepoints

From: Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease

GroupValuesTimeTrend p value
BaselineYear 1Year 2
Total PDNfL16.16 ± 0.6216.11 ± 1.370.2881
MMSE26.82 ± 0.2326.58 ± 0.2526.9 ± 0.250.4523
MoCA25.06 ± 0.2925.05 ± 0.3125.17 ± 0.300.9324
Motor21.32 ± 0.7624.76 ± 0.8425.96 ± 1.03< 0.001
TDNfL15.79 ± 0.8312.62 ± 0.810.1865
MMSE26.99 ± 0.3026.88 ± 0.2827.13 ± 0.290.9128
MoCA25.32 ± 0.3925.35 ± 0.3925.42 ± 0.380.8401
Motor20.99 ± 1.1924.40 ± 1.2025.46 ± 1.37< 0.001
PIGDNfL15.76 ± 0.9618.39 ± 2.150.0474
MMSE26.55 ± 0.4626.06 ± 0.5426.5 ± 0.460.4865
MoCA24.47 ± 0.4824.38 ± 0.6324.61 ± 0.540.8705
Motor22.02 ± 1.2826.17 ± 1.4426.80 ± 1.77< 0.001
  1. Abbreviations: PD Parkinson’s Disease; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; Motor Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores; MoCA Montreal Cognitive Assessment; NfL Neurofilament light chain protein
  2. Values represent the mean ± SD